Artículos de revistas sobre el tema "Fu ci"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Fu ci".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Methot, N. y K. Basler. "Suppressor of fused opposes hedgehog signal transduction by impeding nuclear accumulation of the activator form of Cubitus interruptus". Development 127, n.º 18 (15 de septiembre de 2000): 4001–10. http://dx.doi.org/10.1242/dev.127.18.4001.
Texto completoZhou, Mengmeng, Yuhong Han, Bing Wang, Yong Suk Cho y Jin Jiang. "Dose-dependent phosphorylation and activation of Hh pathway transcription factors". Life Science Alliance 5, n.º 11 (5 de septiembre de 2022): e202201570. http://dx.doi.org/10.26508/lsa.202201570.
Texto completoKöhne, C.-H., J. Wils, M. Lorenz, P. Schöffski, R. Voigtmann, C. Bokemeyer, M. Lutz et al. "Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952". Journal of Clinical Oncology 21, n.º 20 (15 de octubre de 2003): 3721–28. http://dx.doi.org/10.1200/jco.2003.11.122.
Texto completoKabbinavar, Fairooz, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing y Emily Bergsland. "Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer". Journal of Clinical Oncology 21, n.º 1 (1 de enero de 2003): 60–65. http://dx.doi.org/10.1200/jco.2003.10.066.
Texto completoKu, Geoffrey Yuyat, Benjamin Haaland y Gilberto de Lima Lopes. "Cetuximab (C225) in the first-line treatment of advanced colorectal cancer (CRC) patients (Pts) with K-ras wild-type (WT) tumors: Does the choice and schedule of fluoropyrimidine (Fp) matter?" Journal of Clinical Oncology 30, n.º 4_suppl (1 de febrero de 2012): 576. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.576.
Texto completoWang-Gillam, Andrea, Chung-Pin Li, Gyorgy Bodoky, Andrew Dean, Yang-Shen Shan, Gayle S. Jameson, Teresa Macarulla et al. "Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy." Journal of Clinical Oncology 34, n.º 4_suppl (1 de febrero de 2016): 417. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.417.
Texto completoWagner, Anna D., Wilfried Grothe, Johannes Haerting, Gerhard Kleber, Axel Grothey y Wolfgang E. Fleig. "Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data". Journal of Clinical Oncology 24, n.º 18 (20 de junio de 2006): 2903–9. http://dx.doi.org/10.1200/jco.2005.05.0245.
Texto completoArkenau, Hendrik-Tobias, Dirk Arnold, Jim Cassidy, Eduardo Diaz-Rubio, Jean-Yves Douillard, Howard Hochster, Andrea Martoni et al. "Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials". Journal of Clinical Oncology 26, n.º 36 (20 de diciembre de 2008): 5910–17. http://dx.doi.org/10.1200/jco.2008.16.7759.
Texto completoNam, Ki-Woong, Chi Kyung Kim, Tae Jung Kim, Kyungmi Oh, Moon-Ku Han, Sang-Bae Ko y Byung-Woo Yoon. "FLAIR vascular hyperintensities predict early ischemic recurrence in TIA". Neurology 90, n.º 9 (31 de enero de 2018): e738-e744. http://dx.doi.org/10.1212/wnl.0000000000005034.
Texto completoPoplin, Elizabeth A., Jacqueline K. Benedetti, Norman C. Estes, Daniel G. Haller, Robert J. Mayer, Richard M. Goldberg, Geoffrey R. Weiss, Saul E. Rivkin y John S. Macdonald. "Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer". Journal of Clinical Oncology 23, n.º 9 (20 de marzo de 2005): 1819–25. http://dx.doi.org/10.1200/jco.2005.04.169.
Texto completoSisson, Barbara E., Suzanne L. Ziegenhorn y Robert A. Holmgren. "Regulation of Ci and Su(fu) nuclear import in Drosophila". Developmental Biology 294, n.º 1 (junio de 2006): 258–70. http://dx.doi.org/10.1016/j.ydbio.2006.02.050.
Texto completoSchilsky, Richard L., Jeremey Levin, William H. West, Alfred Wong, Bruce Colwell, Michael P. Thirlwell, Rafat H. Ansari et al. "Randomized, Open-Label, Phase III Study of a 28-Day Oral Regimen of Eniluracil Plus Fluorouracil Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Therapy in Patients With Metastatic/Advanced Colorectal Cancer". Journal of Clinical Oncology 20, n.º 6 (15 de marzo de 2002): 1519–26. http://dx.doi.org/10.1200/jco.2002.20.6.1519.
Texto completoHoning, Judith, Justin Smit, Christina Muijs, Johannes Burgerhof, Jannet Beukema, John Theodorus Plukker y Geke Hospers. "A comparison of carboplatin with paclitaxel and cisplatinum with 5-fluorouracil in definitive chemoradiotherapy in esophageal cancer patients." Journal of Clinical Oncology 32, n.º 3_suppl (20 de enero de 2014): 104. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.104.
Texto completoSultana, Asma, Catrin Tudur Smith, David Cunningham, Naureen Starling, John P. Neoptolemos y Paula Ghaneh. "Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer". Journal of Clinical Oncology 25, n.º 18 (20 de junio de 2007): 2607–15. http://dx.doi.org/10.1200/jco.2006.09.2551.
Texto completoRao, Sheela, Francesco Sclafani, Cathy Eng, Richard A. Adams, Marianne G. Guren, David Sebag-Montefiore, Al Benson et al. "International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct". Journal of Clinical Oncology 38, n.º 22 (1 de agosto de 2020): 2510–18. http://dx.doi.org/10.1200/jco.19.03266.
Texto completoSchmoll, Hans-Joachim, Josep Tabernero, Jean Alfred Maroun, Filippo G. De Braud, Timothy Jay Price, Eric Van Cutsem, Mark Hill, Silke Hoersch, Karen Rittweger y Daniel G. Haller. "Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA)." Journal of Clinical Oncology 30, n.º 4_suppl (1 de febrero de 2012): 388. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.388.
Texto completoDouillard, Jean-Yves, Paulo M. Hoff, Jamey R. Skillings, Peter Eisenberg, Neville Davidson, Peter Harper, Mark D. Vincent et al. "Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer". Journal of Clinical Oncology 20, n.º 17 (1 de septiembre de 2002): 3605–16. http://dx.doi.org/10.1200/jco.2002.04.123.
Texto completoYang Seoung Duk. "A Study on the Ci-Fu Thoughts of Xie-Ling-Yun". Journal of Chinese Language and Literature ll, n.º 54 (diciembre de 2009): 83–104. http://dx.doi.org/10.15792/clsyn..54.200912.83.
Texto completoYang, Seoung Duk. "A Study on The theory of Dong-Jin,s Ci-Fu". JOURNAL OF CHINESE HUMANITIES 76 (31 de diciembre de 2020): 223–43. http://dx.doi.org/10.35955/jch.2020.12.76.223.
Texto completoCassidy, J., N. Scotto y E. Diaz-Rubio. "Review of completed and ongoing trials of capecitabine-based adjuvant therapy in patients with early-stage colon cancer." Journal of Clinical Oncology 29, n.º 4_suppl (1 de febrero de 2011): 495. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.495.
Texto completoMerchant, Mark, Felix F. Vajdos, Mark Ultsch, Henry R. Maun, Ulrich Wendt, Jennifer Cannon, William Desmarais, Robert A. Lazarus, Abraham M. de Vos y Frederic J. de Sauvage. "Suppressor of Fused Regulates Gli Activity through a Dual Binding Mechanism". Molecular and Cellular Biology 24, n.º 19 (1 de octubre de 2004): 8627–41. http://dx.doi.org/10.1128/mcb.24.19.8627-8641.2004.
Texto completoMaisey, Nick, Ian Chau, David Cunningham, Andrew Norman, Matt Seymour, Tamas Hickish, Tim Iveson et al. "Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer". Journal of Clinical Oncology 20, n.º 14 (15 de julio de 2002): 3130–36. http://dx.doi.org/10.1200/jco.2002.09.029.
Texto completoBertagnolli, Monica M., Donna Niedzwiecki, Carolyn C. Compton, Hejin P. Hahn, Margaret Hall, Beatrice Damas, Scott D. Jewell et al. "Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803". Journal of Clinical Oncology 27, n.º 11 (10 de abril de 2009): 1814–21. http://dx.doi.org/10.1200/jco.2008.18.2071.
Texto completoWang-Gillam, Andrea, Richard Hubner, Beloo Mirakhur, Floris A. de Jong, Bruce Belanger y Li-Tzong Chen. "Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy." Journal of Clinical Oncology 36, n.º 4_suppl (1 de febrero de 2018): 388. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.388.
Texto completoTaïeb, Julien, Tim Maughan, Carsten Bokemeyer, Eric Van Cutsem, Thomas Brodowicz, Gunnar Folprecht, Regina Esser, Michael Schlichting y Josep Tabernero. "Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 3574. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3574.
Texto completoWagner, A. D., W. Grothe, J. Haerting, G. Kleber, A. Grothey y W. E. Fleig. "Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis". Journal of Clinical Oncology 25, n.º 18_suppl (20 de junio de 2007): 4555. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.4555.
Texto completoSchmoll, Hans-Joachim, Josep Tabernero, Jean Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Silke Hoersch, Karen Rittweger y Daniel G. Haller. "Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial". Journal of Clinical Oncology 33, n.º 32 (10 de noviembre de 2015): 3733–40. http://dx.doi.org/10.1200/jco.2015.60.9107.
Texto completoSizer, B., A. Makris, C. Barone, P. Mainwaring y P. Eggleton. "QoL and resource use analysis of tegafur-uracil/LV or 5-FU/LV in first-line metastatic colorectal cancer (mCRC): Final results of a multicenter phase II study". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 3631. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.3631.
Texto completoKöhne, C. H., E. van Cutsem, J. Wils, C. Bokemeyer, M. El-Serafi, M. P. Lutz, M. Lorenz et al. "Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986". Journal of Clinical Oncology 23, n.º 22 (1 de agosto de 2005): 4856–65. http://dx.doi.org/10.1200/jco.2005.05.546.
Texto completoPeng, Chengwei, Saad Saffo, Michael Shusterman, Daniel Jacob Becker, Jordan Berlin, Paul Eliezer Oberstein, Anil Nagar y Shun Yu. "Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer." Journal of Clinical Oncology 41, n.º 4_suppl (1 de febrero de 2023): 59. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.59.
Texto completoFuchs, Charles S., Donna Niedzwiecki, Harvey J. Mamon, Joel E. Tepper, Xing Ye, Richard S. Swanson, Peter C. Enzinger et al. "Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)". Journal of Clinical Oncology 35, n.º 32 (10 de noviembre de 2017): 3671–77. http://dx.doi.org/10.1200/jco.2017.74.2130.
Texto completoLi, Jia-yi, Xuan-zhang Huang, Peng Gao, Xiao-wan Chen, Yong-xi Song, Xing-er Lv, Yv Fu, Qiong Xiao y Zhen-ning Wang. "Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment". BioMed Research International 2021 (27 de marzo de 2021): 1–21. http://dx.doi.org/10.1155/2021/8852699.
Texto completoWang, Aiqing. "Cliché-ridden Online Danmei Fiction? A Case Study of Tianguan ci fu". Acta Asiatica Varsoviensia 35 (2022): 281–314. http://dx.doi.org/10.60018/acasva.iray5065.
Texto completoSchmidt, Jan, Ulrich Abel, Jürgen Debus, Sabine Harig, Katrin Hoffmann, Thomas Herrmann, Detlef Bartsch et al. "Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma". Journal of Clinical Oncology 30, n.º 33 (20 de noviembre de 2012): 4077–83. http://dx.doi.org/10.1200/jco.2011.38.2960.
Texto completoModest, Dominik Paul, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Alexander Koenig, Ludwig Fischer von Weikersthal et al. "FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses." Journal of Clinical Oncology 42, n.º 16_suppl (1 de junio de 2024): 3506. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3506.
Texto completoYothers, Greg, Patricia A. Ganz, Samia H. Lopa, Clifford Y. Ko, D. Lawrence Wickerham y Norman Wolmark. "Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04." Journal of Clinical Oncology 30, n.º 4_suppl (1 de febrero de 2012): 391. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.391.
Texto completoSargent, Daniel J., Silvia Marsoni, Genevieve Monges, Stephen N. Thibodeau, Roberto Labianca, Stanley R. Hamilton, Amy J. French et al. "Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer". Journal of Clinical Oncology 28, n.º 20 (10 de julio de 2010): 3219–26. http://dx.doi.org/10.1200/jco.2009.27.1825.
Texto completoLiu, Guo-Chen, Jun-Ping Yan, Qing He, Xin An, Zhi-Zhong Pan y Pei-Rong Ding. "Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis". Gastroenterology Research and Practice 2016 (2016): 1–10. http://dx.doi.org/10.1155/2016/1798285.
Texto completoFreeman, Karoline, Martin Connock, Ewen Cummins, Tara Gurung, Sian Taylor-Phillips, Rachel Court, Mark Saunders, Aileen Clarke y Paul Sutcliffe. "Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion". Health Technology Assessment 19, n.º 91 (noviembre de 2015): 1–322. http://dx.doi.org/10.3310/hta19910.
Texto completoZafar, Amna, Zsofia D. Drobni, Matthew Lei, Carlos A. Gongora, Thiago Quinaglia, Uvette Y. Lou, Ramya Mosarla et al. "The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm". PLOS ONE 17, n.º 4 (7 de abril de 2022): e0265767. http://dx.doi.org/10.1371/journal.pone.0265767.
Texto completoIkawati, Muthi y Endah Puji Septisetyani. "Pentagamavunone-0 (PGV-0), a Curcumin Analog, Enhances Cytotoxicity of 5-Fluorouracil and Modulates Cell Cycle in WiDr Colon Cancer Cells". Indonesian Journal of Cancer Chemoprevention 9, n.º 1 (28 de febrero de 2018): 23. http://dx.doi.org/10.14499/indonesianjcanchemoprev9iss1pp23-31.
Texto completoSholihah, Imroatus, Meirizky Zulharini S., Amalia Miranda, Refki Riswansyah y Riris Istighfari Jenie. "Jure Leaf Extract (Nerium indium Mill.) Increased 5-Fluorouracil Sensitivity through Inhibition of NF-κB Activation and Transporter Protein in WiDr Colon Cancer Cell". Indonesian Journal of Cancer Chemoprevention 7, n.º 3 (1 de febrero de 2017): 87. http://dx.doi.org/10.14499/indonesianjcanchemoprev7iss3pp87-92.
Texto completoAl-Thani, Hassan, Ayman El-Menyar, Valsa Koshy, Ahmed Hussein, Ahmed Sharaf, Mohammad Asim y Ahmed Sadek. "Implications of Foot Ulceration in Hemodialysis Patients: A 5-Year Observational Study". Journal of Diabetes Research 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/945075.
Texto completoMohamed, Yehia I., Aliya Qayyum, Manal Hassan, Lianchun Xiao, Dan G. Duda, Rikita Hatia, Sunyoung S. Lee et al. "Treatment outcome and prognostic indicators in 26 cases of fibrolamellar hepatocellular carcinoma under interferon based therapy." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): e16626-e16626. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e16626.
Texto completoHaller, Daniel G., Josep Tabernero, Jean Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Frank Gilberg, Karen Rittweger y Hans-Joachim Schmoll. "Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer". Journal of Clinical Oncology 29, n.º 11 (10 de abril de 2011): 1465–71. http://dx.doi.org/10.1200/jco.2010.33.6297.
Texto completoBang, Kyunghye, Jaekyung Cheon, Jae Ho Jeong, Hyeon-Su Im, Kyu-Pyo Kim, Baek-Yeol Ryoo y Changhoon Yoo. "Efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin after progression on conventional irinotecan-containing chemotherapy for metastatic pancreatic adenocarcinoma." Journal of Clinical Oncology 39, n.º 3_suppl (20 de enero de 2021): 382. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.382.
Texto completoBang, Kyunghye, Jaekyung Cheon, Jae Ho Jeong, Hyeon-Su Im, Kyu-pyo Kim, Baek-Yeol Ryoo y Changhoon Yoo. "Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy". Therapeutic Advances in Medical Oncology 13 (enero de 2021): 175883592110030. http://dx.doi.org/10.1177/17588359211003053.
Texto completoMcCaffrey, J. A., S. Hilton, M. Mazumdar, S. Sadan, M. Heineman, J. Hirsch, W. K. Kelly, H. I. Scher y D. F. Bajorin. "Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma." Journal of Clinical Oncology 15, n.º 6 (junio de 1997): 2449–55. http://dx.doi.org/10.1200/jco.1997.15.6.2449.
Texto completoTesta, Luca, Azeem Latib, Nedy Brambilla, Federico De Marco, Claudia Fiorina, Marianna Adamo, Cristina Giannini et al. "Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis". European Heart Journal 41, n.º 20 (6 de enero de 2020): 1876–86. http://dx.doi.org/10.1093/eurheartj/ehz925.
Texto completoHendlisz, Alain, Marc Van den Eynde, Marc Peeters, Geert Maleux, Bieke Lambert, Jaarke Vannoote, Katrien De Keukeleire et al. "Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy". Journal of Clinical Oncology 28, n.º 23 (10 de agosto de 2010): 3687–94. http://dx.doi.org/10.1200/jco.2010.28.5643.
Texto completo